Additionally, a few antibodies and Kirsten rat sarcoma (KRAS) inhibitors are used in NSCLC treatment (Figure 2) (Wishart et al., 2018; NIH, 20231). This evidence concerns the gene KRAS and non-small cell lung carcinoma.